FDA
-
-
-
-
-
-
-
NANOBIOTIX Provides First Quarter Operational and Financial Update
-
-
-
-
-
-
-
NANOBIOTIX Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
-
-
-
-
-
-
-
Nordic Nanovector's Betalutin® Receives Fast-track Designation from US FDA for Marginal Zone Lymphoma
-
-
-
-
-
-
-
Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021
-
-
-
-
-
-
-
NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019
-
-
-
-
-
-
-
Nanobiotix announces first quarter 2019 revenue
-
-
-
-
-
-
-
Nanobiotix and MD Anderson Cancer Center Announce a Large-Scale, Comprehensive Clinical Collaboration on NBTXR3
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

